Diabetic Peripheral Neuropathy (DPN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Diabetic Peripheral Neuropathy (DPN) Market Outlook

Thelansis’s “Diabetic Peripheral Neuropathy (DPN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Diabetic Peripheral Neuropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Diabetic Peripheral Neuropathy (DPN) Overview

Diabetic peripheral neuropathy (DPN) is a common and chronic complication of diabetes, leading to distressing and expensive clinical issues such as foot ulcers, leg amputations, and neuropathic pain (painful DPN). This condition is linked to increased mortality and mainly results in diabetic foot ulcers and neuropathic pain. Typically, DPN is the most prevalent form of neuropathy in diabetes, affecting both sensory and motor nerves in a peripheral distribution. However, individuals' impact on small and large sensory and motor fibers varies. DPN's most significant risk factors are the duration of diabetes and glycemic control. Additional risk factors for cardiovascular disease, such as obesity, hypertension, smoking, and dyslipidemia, are also associated with DPN. The pathogenesis of DPN is complex and not fully understood. DPN risk is low at the diagnosis of type 1 diabetes, so foot screening should begin five years after diagnosis. Limited treatments are available to reverse the underlying nerve damage that causes DPN. Therefore, preventing DPN is a crucial aspect of diabetes care, and the American Diabetes Association (ADA) recommends achieving optimal glucose control in both type 1 and type 2 diabetes to prevent or slow the progression of DPN.

• In the general US population aged 40 years or older, the overall prevalence of peripheral neuropathy (PN) defined by monofilament insensitivity was 13.5% in 2010, which equated to 18.6 million US adults.
• Among adults aged 40 or older, the prevalence of PN was 28.4% in individuals with diabetes (4.2 million) and 11.8% in those without diabetes (14.4 million).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: